Chronic kidney disease-associated pruritus (CKD-aP) represents a substantial unmet need as it affects a significant proportion of patients with advanced chronic kidney disease and end-stage renal disease. Itching can be debilitating, leading to poor quality of life, sleep disturbances, and psychological distress. Our experts, Drs. Steven Fishbane, Thilo Krüger, and Lucio Manenti, discuss real-world case presentations that illustrate how to incorporate and evaluate novel therapeutic approaches to enhance quality of life in patients with CKD-aP.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Thilo Krüger, MD, PhD
Deputy Chief Medical Officer
Internist and Nephrologist
DaVita Clinical Research Germany GmbH
Düsseldorf, GermanyNothing to disclose.
Faculty:
Steven N. Fishbane, MD
Chief, Division of Kidney Disease and Hypertension, Northwell Health
Vice President, Network Dialysis Services, Northwell Health
Professor of Medicine, Donald and Barbara Zucker School of Medicine
Hofstra/Northwell
Great Neck, NY, United StatesConsulting Fees: Akebia, AstraZeneca, Cara Therapeutics, FibroGen
Contracted Research: Akebia, Ardelyx, AstraZeneca, Cara Therapeutics, Corvidia Therapeutics, Gilead Sciences, FibroGen, MegaPro BiomedicalLucio Manenti, MD, PhD
Nephrology Unit
Azienda Ospedaliero-Universitaria di Parma
Parma, ItalyConsulting Fees: Alexion Pharmaceuticals, CSL Vifor, GSK
Reviewers/Content Planners/Authors:
- Megan Clem has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Ann Early has nothing to disclose.
- Amanda Hilferty has nothing to disclose.
- Hany Ibrahim, MD, has nothing to disclose.
- Tim Person has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Describe the role of homeostasis of the κ-opioid receptor (KOR) and μ-opioid receptor (MOR) in the pathogenesis of chronic kidney disease-associated pruritus (CKD-aP)
- Apply recent clinical trial data for the effective integration of KOR agonists into management plans for patients with CKD-aP
- Evaluate the impact of treatment on itch severity and patients’ health-related quality of life utilizing validated itch scales
Target Audience
This activity is designed to meet the educational needs of nephrologists, dermatologists, nephrology nurses, and dialysis nurses.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from CSL Vifor.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Facebook Comments